clinical trial · NCT05108922
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Eli Lilly and Company·phase3·completed·n = 148
Mild Cognitive Impairment (MCI)Alzheimer DiseaseDonanemabAducanumab
brief summary
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
started
Nov 16, 2021
primary completion
Sep 9, 2022
completion
Sep 19, 2023
last updated
Nov 29, 2024
official title
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol